Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence

Bibliographic Details
Main Authors:	Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	Human Vaccines & Immunotherapeutics
Online Access:	http://dx.doi.org/10.1080/21645515.2022.2149015

Similar Items

A racing heart post‐Pfizer/BioNTech BNT162b2
by: Hooi Khee Teo, et al.
Published: (2022-10-01)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
by: Giancarlo Ripabelli, et al.
Published: (2023-01-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-12-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01)

Bibliometric Analysis of Pfizer-BioNTech (BNT162B2): A COVID-19 Vaccine
by: Waseem Hassan, et al.
Published: (2021-09-01)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
by: Nazmul Islam, et al.
Published: (2022-05-01)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021-12-01)

Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?
by: Gerardo Cazzato, et al.
Published: (2022-03-01)

Large Hemorrhagic Pericardial Effusion and Cardiac Tamponade Following BNT162b2 (BioNTech/Pfizer) Vaccine
by: Hien Nguyen, et al.
Published: (2022-11-01)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
by: Toshiyuki Sumi, et al.
Published: (2021-11-01)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
by: Rumiko Shimazawa, et al.
Published: (2021-12-01)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
by: Michael Jahn, et al.
Published: (2021-04-01)

Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis
by: Jewel Maria Sabu, et al.
Published: (2022-11-01)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
by: Michael Jahn, et al.
Published: (2022-02-01)

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
by: Abdallah Damin Abukhalil, et al.
Published: (2023-01-01)

A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome
by: Yoshihiro Matsuda, et al.
Published: (2023-06-01)

Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
by: Markus Aldén, et al.
Published: (2022-02-01)

Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study
by: Prisha Patel, et al.
Published: (2023-11-01)

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review
by: Karen Cortés-Sarabia, et al.
Published: (2022-06-01)

Longitudinal study of antibody response following SARS-CoV-2 vaccination with Pfizer-BioNTech BNT162b2
by: Robles Navas Leandra J., et al.
Published: (2023-08-01)

Friend or foe—The Pfizer‐BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis
by: Bianca Maria Wahlen, et al.
Published: (2022-07-01)

Humoral immunity after Pfizer/BioNTech BNT162b2 vaccine in healthcare workers of ASL Roma 2 (Italy)
by: Eliana Giberna, et al.
Published: (2021-10-01)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy
by: Giancarlo Ripabelli, et al.
Published: (2022-11-01)

Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines
by: Xuhua Xia
Published: (2021-07-01)

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
by: Shin-Jie Yong, et al.
Published: (2022-07-01)

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series
by: Elif Karatas, MD, et al.
Published: (2023-02-01)

Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
by: Patrick D. M. C. Katoto, et al.
Published: (2022-11-01)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
by: Johannes Korth, et al.
Published: (2021-04-01)

Hypereosinophilic Syndrome Following the BNT162b2 (BioNTech/Pfizer) Vaccine Successfully Treated with Mepolizumab: A Case Report and Review of the Literature
by: Ariela Hoxha, et al.
Published: (2023-03-01)

Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
by: Patrick DMC. Katoto, et al.
Published: (2023-01-01)

Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses
by: Patrick DMC Katoto, et al.
Published: (2023-12-01)

Childhood primary angiitis of the central nervous system following COVID-19 vaccination (BNT162b2/Pfizer-BioNtech): A case report
by: Toshiki Ariyoshi, et al.
Published: (2023-08-01)

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
by: Jose W. Ricardo, MD, et al.
Published: (2021-11-01)

Recurring Weakness in Rhabdomyolysis Following Pfizer–BioNTech Coronavirus Disease 2019 mRNA Vaccination
by: Motoya Kimura, et al.
Published: (2022-06-01)

Erythematous reaction of the BCG site to Pfizer‐BioNTech COVID‐19 vaccine
by: Yuta Ito, et al.
Published: (2023-10-01)

Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine
by: Olivia G. Cohen, et al.
Published: (2021-11-01)

Focal segmental glomerulosclerosis following the Pfizer-BioNTech COVID-19 vaccine
by: Cho A Lim, et al.
Published: (2022-03-01)

Acute macular neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination
by: Daniel A. Valenzuela, et al.
Published: (2021-12-01)

Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report
by: Ryo Kaimori, et al.
Published: (2022-10-01)